title: Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode.
abstract: Human microsomal cytochrome P450 (CYP) 2E1 is widely known for its ability to oxidize >70 different, mostly compact, low molecular weight drugs and other xenobiotic compounds. In addition CYP2E1 oxidizes much larger C9-C20 fatty acids that can serve as endogenous signaling molecules. Previously structures of CYP2E1 with small molecules revealed a small, compact CYP2E1 active site, which would be insufficient to accommodate medium and long chain fatty acids without conformational changes in the protein. In the current work we have determined how CYP2E1 can accommodate a series of fatty acid analogs by cocrystallizing CYP2E1 with omega-imidazolyl-octanoic fatty acid, omega-imidazolyl-decanoic fatty acid, and omega-imidazolyl-dodecanoic fatty acid. In each structure direct coordination of the imidazole nitrogen to the heme iron mimics the position required for native fatty acid substrates to yield the omega-1 hydroxylated metabolites that predominate experimentally. In each case rotation of a single Phe(298) side chain merges the active site with an adjacent void, significantly altering the active site size and topology to accommodate fatty acids. The binding of these fatty acid ligands is directly opposite the channel to the protein surface and the binding observed for fatty acids in the bacterial cytochrome P450 BM3 (CYP102A1) from Bacillus megaterium. Instead of the BM3-like binding mode in the CYP2E1 channel, these structures reveal interactions between the fatty acid carboxylates and several residues in the F, G, and B' helices at successive distances from the active site.
authors.affiliation: Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, USA.
authors.forename: Patrick R
authors.initials: PR
authors.lastname: Porubsky
authors.forename: Kevin P
authors.initials: KP
authors.lastname: Battaile
authors.forename: Emily E
authors.initials: EE
authors.lastname: Scott
mesh_terms: D018360:Crystallography, X-Ray; D019392:Cytochrome P-450 CYP2E1 / Q000737:chemistry* / Q000378:metabolism*; D005227:Fatty Acids / Q000737:chemistry* / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D008958:Models, Molecular; D011485:Protein Binding; D017433:Protein Structure, Secondary; D012984:Software
chemical_list: D005227:Fatty Acids; D008024:Ligands; D019392:Cytochrome P-450 CYP2E1
references.citation: Nature. 1996 May 23;381(6580):272
references.pmid: 8692262
references.citation: Circ Res. 2000 Jul 7;87(1):60-5
references.pmid: 10884373
references.citation: Biochemistry. 2001 Nov 13;40(45):13456-65
references.pmid: 11695892
references.citation: Methods Enzymol. 1997;276:307-26
references.pmid: 27754618
references.citation: J Biol Chem. 2003 Mar 14;278(11):9761-7
references.pmid: 12519760
references.citation: J Biol Chem. 2008 Nov 28;283(48):33698-707
references.pmid: 18818195
references.citation: Arch Biochem Biophys. 1997 Jan 1;337(1):1-7
references.pmid: 8990261
references.citation: Toxicol Appl Pharmacol. 2000 Nov 1;168(3):268-79
references.pmid: 11042099
references.citation: Fundam Clin Pharmacol. 1998;12(5):553-8
references.pmid: 9794154
references.citation: Nat Struct Biol. 1997 Feb;4(2):140-6
references.pmid: 9033595
references.citation: Biochem J. 2005 Sep 15;390(Pt 3):719-27
references.pmid: 15916533
references.citation: J Biochem. 1994 Feb;115(2):338-44
references.pmid: 8206883
references.citation: Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
references.pmid: 16369096
references.citation: Toxicol Appl Pharmacol. 1998 Sep;152(1):276-81
references.pmid: 9772223
references.citation: J Lipid Res. 1999 Nov;40(11):1990-7
references.pmid: 10553002
references.citation: Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
references.pmid: 15299926
references.citation: Biochemistry. 2000 May 16;39(19):5731-7
references.pmid: 10801323
references.citation: J Biol Chem. 1993 Jun 15;268(17):12912-8
references.pmid: 8509425
references.citation: Am J Physiol. 1999 Sep;277(3):R607-23
references.pmid: 10484476
references.citation: Biochemistry. 2008 Mar 25;47(12):3662-70
references.pmid: 18298086
references.citation: BMC Bioinformatics. 2006 Jun 22;7:316
references.pmid: 16792811
references.citation: J Comb Chem. 2001 Mar-Apr;3(2):205-15
references.pmid: 11300862
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15696-701
references.pmid: 18838690
references.citation: Org Biomol Chem. 2005 Aug 7;3(15):2688-90
references.pmid: 16032346
references.citation: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references.pmid: 15572765
references.citation: J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
references.pmid: 19461840
references.citation: Arch Biochem Biophys. 1995 Jul 10;320(2):289-96
references.pmid: 7625836
references.citation: Am J Physiol. 1996 Oct;271(4 Pt 2):R863-9
references.pmid: 8897975
references.citation: Acta Crystallogr D Biol Crystallogr. 1994 Mar 1;50(Pt 2):178-85
references.pmid: 15299456